Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol. 2017;23(4):340-346.   Published online 2017 Jun 20     DOI: https://doi.org/10.3350/cmh.2016.0070
Citations to this article as recorded by Crossref logo
Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors
Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(7): 732.     CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang
Therapeutic Advances in Medical Oncology.2022; 14: 175883592210994.     CrossRef
A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma
Dashuai Yang, Yang Su, Fangrui Zhao, Chen Chen, Kailiang Zhao, Xiangyun Xiong, Youming Ding
Frontiers in Oncology.2022;[Epub]     CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2021; 36(5): 1317.     CrossRef
Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma
Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi
World Journal of Gastrointestinal Surgery.2021; 13(10): 1245.     CrossRef
Complete Pathological Response of Hepatocellular Carcinoma with Portal Vein Thrombosis Treated with Sorafenib—Report of a Case—
Tetsushi MIZUTANI, Mizuo HASHIMOTO, Hiroaki USUI, Tomoki KOBAYASHI, Motonobu NISHIMURA, Kenji SAKAGUCHI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2021; 82(3): 635.     CrossRef
Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
Piero Colombatto, Coskun Ozer Demirtas, Gabriele Ricco, Luigi Civitano, Piero Boraschi, Paola Scalise, Daniela Cavallone, Filippo Oliveri, Veronica Romagnoli, Patrizia Bleve, Barbara Coco, Antonio Salvati, Lucio Urbani, Ferruccio Bonino, Maurizia Rossana
Cancers.2021; 13(9): 2064.     CrossRef
Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma
Akane Kurosugi, Tetsuhiro Chiba, Terunao Iwanaga, Hidemi Unozawa, Takafumi Sakuma, Naoto Fujita, Kengo Kanayama, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Soichiro Kiyono, Ryo Nakagawa, Naoya Kanogawa, Masato Nakamura, Takayuki Kondo, Tomoko Sa
Kanzo.2021; 62(10): 656.     CrossRef
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection
Alessandra Bertacco, Alessandro Vitale, Claudia Mescoli, Umberto Cillo
Personalized Medicine.2020; 17(2): 83.     CrossRef
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy
Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo
Clinical Journal of Gastroenterology.2020; 13(5): 902.     CrossRef
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai-Wen Huang, Daniel H. Palmer, Yuk Ting Ma, T.R. Jeff Evans, Duncan R.C. Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vinee
Clinical Cancer Research.2020; 26(15): 3936.     CrossRef
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang
Cancer Chemotherapy and Pharmacology.2019; 84(4): 809.     CrossRef
Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene transgenic zebrafish model
Yan Li, Ira Agrawal, Zhiyuan Gong
Disease Models & Mechanisms.2019;[Epub]     CrossRef
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera
Cancer Communications.2018; 38(1): 41.     CrossRef
Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?
Matthias Pinter, Wolfgang Sieghart
memo - Magazine of European Medical Oncology.2018; 11(3): 185.     CrossRef